Sibutramine lost and found
Authors:
- 1 September 2002
- journal article
- research article
- Published by Springer Nature in Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity
- Vol. 7 (3) , 161-167
Abstract
Obesity has now been identified as a chronic disease, a global epidemic (globesity) and a serious public health issue that leads to reduced life expectancy, an increased risk for many serious medical conditions and enormous healthcare costs. The prevalence of obesity and overweight in Italy in 2000 was respectively 9% and 33%, and has grown by 25% over the last five years. Even moderate weight loss can improve obesityrelated morbidity and mortality. In November 1997, the US Food and Drug Administration approved sibutramine, a serotonin and noradrenaline reuptake inhibitor, for the treatment of pathological obesity and the management and maintenance of weight loss. In March 2002, sibutramine was temporarily withdrawn from the Italian market on the basis of 47 adverse event reports received between April and December 2001. However, a worldwide review of efficacy and safety data has shown that the overall risk/benefit profile of sibutramine remains favourable, with the rate of fatal reports involving patients receiving sibutramine being 200 times less than the obese women’s mortality rate in the Nurses’ Health Study. There is strong evidence supporting the usefulness of the correct use of sibutramine in the management of obesity.Keywords
This publication has 35 references indexed in Scilit:
- PCV18 OVERWEIGHT AND OBESITY: THE COST TO SOCIETY AND THE ASSOCIATION WITH BODY MASS INDEXValue in Health, 2002
- Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitorsJournal of Human Hypertension, 2002
- Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet–exercise interventionInternational Journal of Obesity, 2001
- Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trialInternational Journal of Obesity, 2001
- Patterns of long-term weight changes in overweight developing Danish men and women aged between 30 and 60 yearsInternational Journal of Obesity, 1999
- The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restrictionInternational Journal of Obesity, 1999
- 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of HypertensionJournal Of Hypertension, 1999
- Pharmacotherapy for Obesity — Do the Benefits Outweigh the Risks?New England Journal of Medicine, 1996
- Type II Diabetic Subjects Lose Less Weight Than Their Overweight Nondiabetic SpousesDiabetes Care, 1987
- The Effect of Weight Reduction on Blood Pressure, Plasma Renin Activity, and Plasma Aldosterone Levels in Obese PatientsNew England Journal of Medicine, 1981